Tang Helen, Kaplan David E, Mahmud Nadim
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Am J Gastroenterol. 2024 Mar 27. doi: 10.14309/ajg.0000000000002785.
Weight loss is the mainstay of management for patients with metabolic dysfunction-associated steatotic liver disease. We studied the impact of referral to MOVE!, a nationally-implemented behavioral weight loss program, on weight in MASLD patients.
This retrospective cohort study included 102,294 MASLD patients from 125 Veterans Health Administration centers from 2008-2022.
Most patients lost no significant weight or gained weight. Increased engagement with MOVE! was associated with greater hazard of significant weight loss compared to no engagement.
A minority of patients experienced significant weight loss through 5 years using lifestyle interventions alone.
体重减轻是代谢功能障碍相关脂肪性肝病患者管理的主要手段。我们研究了转介至“行动起来！”（一项全国实施的行为减肥计划）对代谢相关脂肪性肝病（MASLD）患者体重的影响。
这项回顾性队列研究纳入了2008年至2022年期间来自125个退伍军人健康管理中心的102,294例MASLD患者。
大多数患者体重没有显著减轻或有所增加。与未参与相比，更多地参与“行动起来！”计划与显著体重减轻的更大风险相关。
少数患者仅通过生活方式干预在5年内实现了显著体重减轻。
